SK-MS10

Phase 2Small molecule

SSK Chemicals Co., Ltd.

SK-MS10 is one of 11 small molecule programs targeting Chronic Gastritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic GastritisActive, not recruiting

Chronic GastritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Chronic Gastritis

#DrugCompanyPhaseTrials

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 2

Mucosta

Otsuka

Phase 3

2 3

DWP14012

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 4

Reference

RRespirent Pharmaceuticals Co Ltd.

Phase 3

1 5

Test

RRespirent Pharmaceuticals Co Ltd.

Phase 3

1 6

DW1903-R1

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 7

HIP2101

Hanmi Pharmaceutical Company Limited

Phase 3

1 8

DW1903

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 9

RLD2101

Hanmi Pharmaceutical Company Limited

Phase 3

1 10

Stillen

Chong Kun Dang Pharmaceutical

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Gastritis1 trial

Study to Assess the Efficacy and Safety of SK-MS10 in Subjects With Acute and Chronic Gastritis

Completed·SSK Chemicals Co., Ltd.·Phase 2·NCT01578811·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SK-MS10. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SK-MS10 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SK-MS10. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SK Chemicals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSK Chemicals Co., Ltd.

SK-MS10

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Gastritis1 trial

References

Drug Info

Quick Facts

Related News